Introduction

Recent clinical evidence suggests that a shorter course of Romosozumab for postmenopausal osteoporosis might be as effective as the standard twelve-month regimen. Traditionally, clinicians recommend a full year of this bone-forming agent to maximize density gains. However, the unique anabolic effects of this sclerostin inhibitor often peak within the first few months of therapy. Consequently, researchers recently evaluated if a brief three-month duration could achieve similar long-term results when transitioned to antiresorptive therapy.

The Study: 3 Months vs. 12 Months

A prospective, non-inferiority trial compared three months of romosozumab followed by nine months of denosumab against twelve months of continuous romosozumab therapy. Specifically, the study enrolled fifty postmenopausal women at high risk for fracture. At the one-year mark, the results were highly significant. The mean change in total hip bone mineral density (BMD) reached 5.7% in the short-course group compared to 6.0% in the standard twelve-month group. This finding officially met the predefined non-inferiority threshold, suggesting that the initial months drive the primary hip BMD benefits.

Advantages of Short-Term Romosozumab for postmenopausal osteoporosis

Shortening the duration of romosozumab treatment offers several potential benefits for both patients and healthcare systems. Firstly, it reduces the substantial financial cost associated with monthly clinic-administered injections. Secondly, it may mitigate long-term concerns regarding cardiovascular safety which sometimes limit the clinical use of the drug. Furthermore, clinicians can transition patients earlier to maintenance therapies like denosumab. This flexibility significantly simplifies the long-term management of high-risk patients. Notably, the adverse event profiles remained balanced between the two study groups, showing no increased risk with the abbreviated course.

Clinical Implications for Practice

While the standard twelve-month course remains the approved protocol, these findings open the door for more personalized treatment strategies. In regions where cost is a significant barrier, a three-month induction followed by an antiresorptive agent could broaden access to this highly effective therapy. Nevertheless, clinicians should continue to monitor BMD response and adhere to local guidelines when deciding on the optimal treatment sequence for their patients.

Frequently Asked Questions

Is romosozumab available in India?

Yes, romosozumab is available in India under the brand name Evenity. It is typically indicated for postmenopausal women with a history of fracture or those who have failed other osteoporosis therapies.

What is the standard treatment duration for romosozumab?

The standard FDA-approved duration is twelve monthly doses. However, new research indicates that a three-month course followed by denosumab may provide similar hip BMD gains after one year.

Does romosozumab increase cardiovascular risk?

Romosozumab carries a warning regarding potential cardiovascular risks, including myocardial infarction and stroke. Therefore, clinicians generally avoid its use in patients who have had a heart attack or stroke within the preceding year.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Huang YQ et al. In postmenopausal women at high risk for fracture, romosozumab for 3 mo was noninferior to 12 mo for increasing total hip BMD at 1 y. Ann Intern Med. 2026 May 05. doi: 10.7326/ANNALS-26-01143-JC. PMID: 42081814.

Leder BZ, et al. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026 Mar;14(3):216-222. doi: 10.1016/S2213-8587(25)00319-5.